A network meta-analysis evaluating efficacy and adverse events of eight erlotinib-based
therapies (erlotinib+ placebo, erlotinib+ tivantinib, erlotinib+ celecoxib, erlotinib+ …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the
first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the …

In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of
doublet-targeted agents versus single agent is not clear. A systematic review and …

Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …

Background: The meta-analysis aimed to compare the efficacy and safety of erlotinib versus
(vs.) chemotherapy (docetaxel/pemetrexed) as second-line therapy in advanced non-small …

Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …